Effect of a probiotic on blood pressure in grade 1 hypertension (HYPRO): protocol of a randomized controlled study

Anja Mähler, Nicola Wilck, Geraldine Rauch, Ralf Dechend, Dominik N Müller, Anja Mähler, Nicola Wilck, Geraldine Rauch, Ralf Dechend, Dominik N Müller

Abstract

Background: Arterial hypertension is a major risk factor for cardiovascular disease and leads to target organ damage including stroke, heart failure, and kidney disease. About 1.5 billion people worldwide have hypertension, and it is estimated that it causes about 8 million deaths each year. Although there are several drugs available to lower blood pressure (BP), a great proportion of treated patients does not reach recommended treatment targets. Typical antihypertensive drugs target the vessels, the kidneys, and the heart. However, our gut microbiota also influences cardiovascular health, and gut dysbiosis is associated with hypertension. In this study protocol, we investigate the potential BP-lowering effect of a probiotic in patients with grade 1 hypertension.

Methods: This study is an exploratory, randomized, double-blind, placebo-controlled, parallel-group study. One hundred ten patients with grade 1 hypertension (treated or untreated) will be randomized to either the probiotic Vivomixx® or placebo. The primary endpoint is the nocturnal systolic BP measured by ambulatory blood pressure monitoring after 8 weeks adjusted for the baseline value. The secondary endpoints are changes from baseline in nocturnal diastolic BP, antihypertensive medication, fecal microbiome composition, fecal and serum metabolome, immune cell phenotypes, glucose variability after three standardized breakfasts, and health-related quality of life (PROMIS-29). We also assess the safety profile of the intervention.

Discussion: We postulate that various administrated bacteria (Lactobacilli, Bifidobacteria, and Streptococcus thermophilus) convert dietary components into active metabolites that positively affect immune cell function. A reduction of pro-inflammatory immune cell function could promote a BP-lowering effect.

Trial registration: ClinicalTrials.gov NCT03906578 . Registered on 08 April 2019.

Keywords: Blood pressure; Glucose variability; Hypertension; Immune cell phenotype; Metabolome; Microbiome; Probiotic; Randomized controlled trial; Vivomixx®.

Conflict of interest statement

The authors declare no competing interests. The final trial dataset will be available to the investigators. The funders of the study are neither involved in the study design nor the interpretation of the data or the publishing of the results.

References

    1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450. doi: 10.1161/CIRCULATIONAHA.115.018912.
    1. Lawes CM, Vander Hoorn S, Rodgers A, International Society of H Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–1518. doi: 10.1016/S0140-6736(08)60655-8.
    1. Collaborators GBDRF, Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–2323. doi: 10.1016/S0140-6736(15)00128-2.
    1. Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, et al. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J. 2018;39(7):508–579. doi: 10.1093/eurheartj/ehx628.
    1. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8(1):9418. doi: 10.1038/s41598-018-27377-2.
    1. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol. 2003;14(7 Suppl 2):S99–S102. doi: 10.1097/01.ASN.0000070141.69483.5A.
    1. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr. 1996;64(5):767–771. doi: 10.1093/ajcn/64.5.767.
    1. Usinger L, Reimer C, Ibsen H. Fermented milk for hypertension. Cochrane Database Syst Rev. 2012;4:CD008118.
    1. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64(4):897–903. doi: 10.1161/HYPERTENSIONAHA.114.03469.
    1. Chi C, Li C, Wu D, Buys N, Wang W, Fan H, et al. Effects of probiotics on patients with hypertension: a systematic review and meta-analysis. Curr Hypertens Rep. 2020;22(5):33. doi: 10.1007/s11906-020-01041-5.
    1. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–4211. doi: 10.1172/JCI72331.
    1. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331–1340. doi: 10.1161/HYPERTENSIONAHA.115.05315.
    1. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. doi: 10.1186/s40168-016-0222-x.
    1. Buendia JR, Li Y, Hu FB, Cabral HJ, Bradlee ML, Quatromoni PA, et al. Long-term yogurt consumption and risk of incident hypertension in adults. J Hypertens. 2018;36(8):1671–1679.
    1. Buendia JR, Li Y, Hu FB, Cabral HJ, Bradlee ML, Quatromoni PA, et al. Regular yogurt intake and risk of cardiovascular disease among hypertensive adults. Am J Hypertens. 2018;31(5):557–565. doi: 10.1093/ajh/hpx220.
    1. Itani HA, Harrison DG. Memories that last in hypertension. Am J Physiol Renal Physiol. 2015;308(11):F1197–F1199. doi: 10.1152/ajprenal.00633.2014.
    1. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500–507. doi: 10.1161/HYPERTENSIONAHA.109.145094.
    1. Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551(7682):585–589. doi: 10.1038/nature24628.
    1. Bartolomaeus H, Avery EG, Bartolomaeus TUP, Kozhakhmetov S, Zhumadilov Z, Muller DN, et al. Blood pressure changes correlate with short-chain fatty acids production shifts under a synbiotic intervention. Cardiovasc Res. 2020.
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
    1. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17(7):895–904. doi: 10.1046/j.1365-2036.2003.01543.x.
    1. Buuren Sv. Flexible imputation of missing data. Hall Ca, editor: CRC; 2012.
    1. Bartolomaeus TUP, Birkner T, Bartolomaeus H, Löber U, Avery EG, Mähler A, Weber D, Kochlik B, Balogh A, Wilck N, Boschmann M, Müller DN, Markó L, Forslund SK. Quantifying Technical Confounders in Microbiome Studies. Cardiovasc Res. 2020;cvaa128. 10.1093/cvr/cvaa128. Epub ahead of print. PMID: 32374853.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit